Sentences with phrase «of big drug companies»

Approximately three - quarters of all respondents (76 %) and Trump voters (74 %) believe that high drug costs are the result of big drug companies and the deals their lobbyists make.

He then argues that homeopathy satisfies a real demand in healthcare, to the inconvenience of big drug companies, ignoring the fact that selling water and sugar to people is of great convenience to the big homeopathy companies.

As for stem cell research, I don't think you understand the reach of these big drug companies.

Not exact matches

«Far and away the biggest value - creating step that a company can have is evolving from concept to drug,» says Brian Bapty, a biotechnology analyst with Vancouver - based brokerage Raymond James Financial Inc. «It's one of the best businesses to be in, albeit one of the higher - risk businesses.»

It is also restricted almost entirely to Africa, which, unfortunately for its victims, makes it a less attractive target for big drug companies than a host of non-fatal diseases (think erectile dysfunction) that are more common in rich countries.

LONDON / NEW YORK / TOKYO, April 25 - Rare disease specialist Shire said on Wednesday it was willing to recommend a sweetened $ 64 billion offer from Japan's Takeda Pharmaceutical Co to shareholders, in what would be the biggest acquisition of a drug company since 2000..

Add one more name to the new slew of pharma companies trying to counteract the public backlash to big drug price increases: France's Sanofi, a $ 126 billion firm known for its flagship diabetes and vaccines units.

Eagle's Sassouni pointed out that since the big drug companies are losing billions of dollars every year to generic versions and have little to spend on their own research and development, they are looking to buy smaller biotechnology companies that are developing their own products.

But in the past year the drug company's shares have been one of Wall Street's biggest disasters.

In fact, if you believe Ackman's math, Valeant goes from one of the industry's stingiest companies when it comes to R&D, as critics contend, to one of the biggest spenders on drug research.

LONDON / NEW YORK / TOKYO Rare disease specialist Shire said on Wednesday it was willing to recommend a sweetened $ 64 billion offer from Japan's Takeda Pharmaceutical Co to shareholders, in what would be the biggest acquisition of a drug company since 2000.

COPENHAGEN, April 10 Genmab plans to own a bigger share of drugs in its early - stage pipeline as Europe's biggest biotechnology company prepares to reduce its reliance on a blockbuster cancer drug, marketed by partner Johnson & Johnson.

Such big winners stopped showing up a few years ago, leaving the large drug companies watching the calendar for the day when earnings would be hurt by the loss of key patent protections.

A federal crackdown on illicit foreign supplies of human growth hormone has failed to stop rampant misuse, and instead has driven record sales of the drug by some of the world's biggest pharmaceutical companies, an Associated Press investigation shows...

As big pharmaceutical companies find that the patents for some of their blockbuster drugs are expiring, they are desperately reaching out to replenish their drug pipelines.

It was a far bigger credit than most companies start off with, and Chainalysis smartly ran with it, signing up customers like the Federal Bureau of Investigation, the Drug Enforcement Administration, the Internal Revenue Service and Europol to help them catch criminals.

Now Amazon's moves to enter the health care industry have led two major US companies to make one of the biggest deals of the year, signaling major changes to come in the way Americans buy drugs and otherwise manage their health.

LONDON / NEW YORK / TOKYO (Reuters)- Rare disease specialist Shire said on Wednesday it was willing to recommend a sweetened $ 64 billion offer from Japan's Takeda Pharmaceutical Co to shareholders, in what would be the biggest acquisition of a drug company since 2000.

Athenex Inc. said Monday it expects its new factory in Dunkirk to be completed by the end of March 2019, but the drug development company's shares tumbled by 5 percent after its fourth - quarter loss was far bigger than analysts expected.

Kay Abadee, VP of marketing at Axiom, noted that bigger companies were looking particularly for pea proteins with Generally Recognized As Safe (GRAS) certification from the U.S. Food and Drug Administration (FDA).

David Kessler, the former commissioner of the Food and Drug Administration, is calling for a big government - funded research project to help fill in the gaps in genetic pathways in people, which are turning out to be far more complex than expected for illnesses such as heart disease and which may be beyond the ability of private companies and smaller labs to figure out and pay for.

In 2009, BMS took a big risk jumping into the immunotherapy field by acquiring the company Medarex, which brought with it Yervoy, a member of a new class of cancer drugs.

The Canadian drug discovery industry is still small, especially in comparison to the United States, owing to the lack of big pharmaceutical companies conducting research and development in this country.

As well, pharmaceutical companies are looking for new ways to address their two - pronged pipeline problem: many big - name blockbuster drugs will soon lose their patents and, perhaps more important, there is a dearth of new blockbusters headed to the market.

But as its patent expires on November 30 and its first generic competitor takes the stage, Lipitor is also a painful reminder of the challenge that such «patent cliffs» pose for the big drug companies, including Lipitor's developer Pfizer, based in New York.

Like other big pharma companies, Pfizer is partnering with academic institutions to share the risk of drug development and take advantage of academic scientists» broad base of knowledge, says Boston - based Anthony Coyle, vice president of the Centers for Therapeutic Innovation (CTI) at Pfizer.

He will assemble a group of people to voluntarily try an existing drug for a new application before a pharmaceutical company embarks on a bigger, more costly human trial.

Cancer drugs can easily cost $ 150,000 a year, so, in spite of these warnings, the drug company finally moves forward with a big trial of patients.

So I'm a) from the medic profession (Micheal don't kill me I'm an expert of the body and dislike big drug companies and b) I'm an ibs sufferer.

Nina and I are friends as well, even though I say her name wrong, who has also written some books about fat, but there's this national conversation where you have the old school low - fats, mostly paid for by big grain sort of research out there, and you're refuting some of that using very strong academics, randomized controlled trials, and the things that everyone wants, but no one has paid for except for maybe big drug companies and things like that.

Officials also provided a rundown of the companies that have agreed to participate in the endeavor, including big - name corporations such as AT&T, Borders Inc., Century 21 Real Estate Corp., Citibank, Coca - Cola, General Motors, and drug store chain CVS Corp..

Cardinal Health is one of the «big three» drug distribution companies along with McKesson (MCK) and AmerisourceBergen (ABC).

Overview & Current Events Cardinal Health is one of the «Big 3» drug distribution companies along with McKesson (MKC) and AmerisourceBergen (ABC).

Cardinal Health is one of the «Big 3» drug distribution companies along with McKesson (MKC) and AmerisourceBergen (ABC).

The company was listed as a big buy in many spots because of a positive meeting they just had with the FDA in regards to the approval of their new drug to treat Muscular Dystrophy.

However, the Food and Drug Administration (FDA) doesn't really allow pet food companies to add sufficient quantities of these supplements to make a big difference to dogs.

Long - term studies of animal immunity would require a substantial outlay of money — the kind of money that only the drug companies have, and Big Pharma is much more interested in selling more vaccines than challenging the need for them.

Similarly, biomedical and pharmaceutical research is bedazzled by molecular genetics, has sequenced the genome of one or two humans and a handful of other species and invested trillions on very rigidly reductionistic bottom - up research into medicines and diseases — with the result of empty drug pipelines for the big pharma companies in spite of all this investment.

And an extra-special shout to West Virginia AG Darrel McGraw, who has fought valiantly on behalf of those victimized by big drug and tobacco companies, and fended off a very tough challenger who was heavily financed by both the U.S. and West Virginia Chambers of Commerce.

The report provides an interesting breakdown of which drug patents are the most challenged and which of the big pharmaceutical companies are involved in the most litigation.

The article talks about Ruth Lilly, the old reclusive woman who was heir to the Lilly drug company fortune, and who gave a big chunk of her billion... [more]

The article talks about Ruth Lilly, the old reclusive woman who was heir to the Lilly drug company fortune, and who gave a big chunk of her billion dollars to Poetry magazine, which, galvanized so to speak by this influx, transmogrified into the Poetry Foundation.

The drug injury and medical malpractice lawyers at Altman & Altman, LLP believe that the big pharmaceutical companies should be held accountable for their negligence, especially when it comes at the expense of thousands of lives.

Plaintiff hit with big verdicts and the drug company starts looking at getting rid of the uncedrtainty on their balance sheets of so much litigation.

They bravely undertake the risky endeavor of going up against insurance companies, business giants, the health care industry, drug companies, big tobacco, oil and chemical conglomerates — need I go on?

When big drug companies put profits above the safety and wellbeing of the general public, we believe they should be held accountable for their actions.

'' Whether in the pages of the New York Times, the Washington Post, the Wall Street Journal or in Associated Press stories, big corporations such as the banks, oil companies, and drug firms are shown to be, in the words of one concise prosecutor, «lying, cheating and stealing.»

Oncology drug development continues to see a high level of activity and funding across the US, despite an uncertain regulatory environment that has left many Big Pharma companies carefully considering their R&D investments and strategies.

Outside of Immunotherapy there has been a steady rise in companies pushing generic and biosimilar drugs over the last 12 months, something of which the Big Pharma organisations are attempting to resist.

Just recently one big pharmaceutical company was fined 1.2 billion dollars for failing to disclose possible serious side effects of one of their FDA - approved drugs.